Tricol Biomedical, Inc. (formerly HemCon Medical Technologies, Inc.) is a global leader in hemostasis and infection control products with a full range of devices under the HemCon brand indicated for professional medical, surgical, trauma, military, and consumer OTC (over the counter) applications.
Tricol Biomedical, Inc. is a wholly owned independent subsidiary of Tricol International Group, Ltd., a Marshall Islands company, substantially owned by Weifang Tricol Trading Co. Ltd. (www.tricolgroup.com), the largest manufacturer in Asia for microfiber products, with capabilities of manufacturing chitosan microfibers and non-woven sheets and films. Tricol is a strong supplier of microfiber technologies brands worldwide for healthcare and cleaning products. Tricol acquired HemCon Medical Technologies, Inc. in April 2016.
Tricol Biomedical is headquartered in Portland, Oregon with a wholly owned operating subsidiary in Ireland (HemCon Medical Technologies Europe Ltd.) and the Czech Republic (HemCon Medical Technologies CZ s.r.o.).
Tricol Biomedical, Inc. is ISO 13485 certified.
The company and HemCon brand were originally established in 2001 on one simple premise: save and improve lives. With an initial foundation in chitosan based hemostatic solutions, the company has evolved into a global medical products company encompassing a variety of innovative technologies, platforms, and products that serve the acute care, military, and consumer medical markets. The HemCon brand has been synonymous to reliable and safe bleeding control technologies for decades, and the company plans to continuously innovate and bring new technologies and applications to the marketplace, as well as expanding into new markets.
Tricol Biomedical, Inc.’s mission is to provide medical practitioners and consumers worldwide with the highest quality, most cost effective bleeding control solutions and wound care management tools that improve outcomes throughout the continuum of care.
Through the HemCon brand line of products, Tricol is already a world leader in advanced chitosan and oxidized cellulose research and development across the continuum of care. The company is dedicated to expanding its technologies, platforms, and applications to continue to widen its global reach. Today, Tricol develops, manufactures, and markets innovative technologies in advanced wound care, hemorrhage, infection control & wound management. The company has also expanded the use of its chitosan technology to over-the-counter applications and offers dental dressings for oral wounds and surgeries.
Tricol’s commitment to innovation has earned numerous accolades over the years, including most recently the 2016 and 2015 Best of Portland Bandage and Dressing Companies by the Portland Award Program. As well as historically receiving the Frost and Sullivan’s 2006 Technology Innovation of the Year award, the US Army’s Top 10 Inventions Award 2004, the Best of What’s New Award by Popular Science 2003, and in 2007, HemCon was named to Deloitte’s Technology Fast 500, Entrepreneur magazine’s Hot 500, and Inc. magazine’s list of America’s 500 fastest-growing private companies.